Episode 020 The Filtrate is joined by Sadiya Kahn and Paul Welling to discuss the Circulation article that examined the diuretic properties of SGLT2i.
The Filtrate:
Joel Topf
Swapnil Hiremath
Samira Farouk
Matt Sparks
And special guests:
Sadiya Kahn a heart failure specialist at Northwestern University. @HeartDocSadiya
and
Paul Welling a professor of medicine and nephrology at Johns Hopkins. @PAWellingMD
Show Notes:
The Study: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.045691
Coverage at NephJC: http://www.nephjc.com/news/sglt2mechanism
Diuretics for heart failure NEJM Review article: https://www.nejm.org/doi/full/10.1056/nejmra1703100
Don’t say renal: https://www.kidney-international.org/article/S0085-2538(20)30233-7/fulltext?mobileUi=0
Sanjiv “We pronounce HFpEF huff-puff” Shah, MD https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=16814 and https://asecho.org/wp-content/uploads/2016/02/Shah-HFpEF.pdf
Huff Puff is like fetch. It is not going to happen. https://www.youtube.com/watch?v=Pubd-spHN-0
Did he have buttons? https://ajkdblog.org/2019/06/17/muscle-relaxant-use-in-dialysis/
Rate My Room: https://twitter.com/ratemyskyperoom?lang=en
Review on Renal Glucosuria from CJASN: https://cjasn.asnjournals.org/content/5/1/133 and another from the National Organizations of Rare Disorders: https://rarediseases.org/rare-diseases/renal-glycosuria/
Mechanism of Impaired Natriuretic Response to Furosemide during Prolonged Therapy: https://pubmed.ncbi.nlm.nih.gov/2811065/
Two studies that showed drops in BNP with SGLT2i
DAPA HF: https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
DEFINE HF showing nice reduction BNP with dapagliflozen: https://pubmed.ncbi.nlm.nih.gov/31524498/?dopt=Abstract
Copeptin, what is it? https://pubmed.ncbi.nlm.nih.gov/18291667/?dopt=Abstract
SIADH treatment with empagliflozen: https://jasn.asnjournals.org/content/31/3/615.abstract and it is JASN not CJASN. My bad.
EVEREST. Tolvaptan for heart failure: https://jamanetwork.com/journals/jama/fullarticle/206251
Remdesivir placebo controlled RCT: https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
Joel’s Remdesivir study: https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2015301
Swap showing a lot of skepticism to the Lancet HCQ data even before the retraction (which happened after this recording) https://www.the-scientist.com/news-opinion/lancet-retracts-surgispheres-study-on-hydroxychloroquine-67613
Baclofen is dangerous https://www.kidney-international.org/article/S0085-2538(20)30552-4/abstract